Opendata, web and dolomites

TransBioLine SIGNED

Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TransBioLine" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT ZURICH 

Organization address
address: RAMISTRASSE 71
city: ZURICH
postcode: 8006
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 27˙906˙491 €
 EC max contribution 13˙999˙997 € (50%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2024-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT ZURICH CH (ZURICH) coordinator 2˙424˙271.00
2    SIGNATOPE GMBH DE (REUTLINGEN) participant 1˙990˙000.00
3    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 1˙386˙193.00
4    ABX CRO ADVANCED PHARMACEUTICAL SERVICES FORSCHUNGSGESELLSCHAFT MBH DE (DRESDEN) participant 1˙294˙360.00
5    TAMIRNA GMBH AT (WIEN) participant 1˙231˙000.00
6    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 940˙250.00
7    SYNAPSE RESEARCH MANAGEMENT PARTNERS SL ES (MADRID) participant 900˙000.00
8    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 832˙700.00
9    INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA LU (Esch-sur-Alzette) participant 624˙125.00
10    MLM MEDICAL LABS GMBH DE (MONCHENGLADBACH) participant 604˙800.00
11    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 443˙450.00
12    METAHEPS GMBH DE (PLANEGG) participant 284˙000.00
13    UNIVERSIDAD DE MALAGA ES (MALAGA) participant 246˙452.00
14    SERVICIO ANDALUZ DE SALUD ES (SEVILLA) participant 188˙946.00
15    FUNDACIO PRIVADA INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU ES (BARCELONA) participant 182˙600.00
16    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 109˙475.00
17    LANDSPITALI UNIVERSITY HOSPITAL IS (REYKJAVIK) participant 87˙325.00
18    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 81˙400.00
19    UNIVERSITEIT LEIDEN NL (LEIDEN) participant 79˙150.00
20    UNIVERSIDAD DE SALAMANCA ES (SALAMANCA) participant 69˙500.00
21    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
22    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
23    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
24    MERCK SHARP & DOHME CORP US (WHITEHOUSE STATION NJ) participant 0.00
25    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
26    PFIZER LIMITED UK (SANDWICH) participant 0.00
27    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00

Map

 Project objective

Qualified biomarkers help to optimize drug development and patient safety, yet for the regulatory acceptance of safety biomarkers substantial sample sizes are needed to ensure adequate case and control numbers, and robust evidence sufficient for qualification. To address this challenge, a consortium of leading European research institutions and SMEs has been established. The consortium will generate exploratory and confirmatory data enabling regulatory qualification of new safety biomarkers for application in drug development; establish robust datasets on the DILI, DIKI, DIPI, DIVI and DINI biomarkers to enhance diagnosis of disease; develop and validate assays for new safety biomarkers; implement profiles of circulating miRNAs as tissue and mechanism specific diagnostic tool; have key safety biomarkers accepted as qualified drug development tools by EMA, FDA, and PMDA. Given the significant expertise available across the consortium, the group will be able to tackle the key challenges related to successful biomarker qualification. A key driving principle of the consortium is cross-linking via existing networks of top profile research institutions, as well as capitalizing on existing data and resources. The Consortium is embedded into a network of international research collaborations such as the Pro-Euro-DILI-registry, TransQST, eTRANSAFE, the i2b2 tranSMART Foundation, the CIOMS DILI working group, EPoS, LITMUS, and BBMRI. To optimize regulatory interaction, we intend to continue our successful collaboration with non-European consortia such as PSTC, the FNIH Biomarkers Consortium, and US DILIN. A key expected result of the consortium will be a “Safety Biomarker Factory”, regularly qualifying new markers, with an associated “Safety Biomarker Warehouse”, providing to the scientific community, industry, and patients detailed data and information, and knowledge across a large spectrum of advanced safety biomarkers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRANSBIOLINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRANSBIOLINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

RADAR-AD (2019)

Remote Assessment of Disease and Relapse – Alzheimer’s Disease

Read More  

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More